Clene's CNM-Au8 Shows Promising Brain Energy Improvements in Multiple Sclerosis Patients
Clene Inc. presented positive trial results demonstrating that its investigational therapy CNM-Au8 significantly improved brain energy metabolism in multiple sclerosis patients, potentially offering a new approach to slowing disease progression by addressing underlying bioenergetic failure.
Clene Inc. (NASDAQ: CLNN) revealed significant findings from its REPAIR-MS trial at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Barcelona, showing that CNM-Au8 treatment led to substantial improvements in brain energy metabolism across multiple sclerosis patient populations. The combined results demonstrated that CNM-Au8 significantly enhanced brain NAD+/NADH ratios, a critical biomarker of cellular energetic capacity, in both relapsing and non-active progressive MS patients.
The treatment produced meaningful changes in brain NAD+ and NADH fractions, with researchers identifying important correlations between baseline brain energy metabolism and key clinical measures including disability status, cognitive function, and motor performance. These findings suggest that addressing bioenergetic dysfunction could represent a fundamental approach to modifying MS progression. The safety profile of CNM-Au8 was favorable, with the therapy being well tolerated by patients throughout the trial period.
For more detailed information about the company's research and development programs, visit https://www.clene.com. The positive safety data reinforces CNM-Au8's potential as a disease-modifying therapy that targets the underlying mitochondrial dysfunction observed in neurodegenerative conditions. As a late clinical-stage biopharmaceutical company, Clene focuses on developing treatments that improve mitochondrial health and protect neuronal function across various neurodegenerative diseases including amyotrophic lateral sclerosis and Parkinson's disease in addition to multiple sclerosis.
Additional news and updates regarding Clene's progress are available through the company's newsroom at https://ibn.fm/CLNN. CNM-Au8 represents a first-in-class investigational therapy that operates through a novel mechanism targeting mitochondrial function and the NAD pathway while simultaneously reducing oxidative stress. This dual approach to enhancing central nervous system cell survival and function distinguishes it from existing MS treatments that primarily focus on immune modulation rather than addressing cellular energy deficits.
The presentation at ECTRIMS 2025 marks an important milestone in understanding how bioenergetic failure contributes to MS progression and how therapeutic interventions like CNM-Au8 might slow disease advancement by restoring cellular energy balance. The correlation between improved energy metrics and clinical outcomes provides compelling evidence for further investigation of this therapeutic approach in larger clinical trials.